ELND007 is a metabolically stable γ-secretase inhibitor that selectively inhibits amyloid-beta (Aβ) production while sparing Notch signaling; it effectively reduces Aβ levels in vitro and in vivo, demonstrating significant potency in lowering Aβ levels in cerebrospinal fluid (CSF) and showing potential therapeutic effects for Alzheimer's disease.